Abstract
Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor used in the treatment of high-risk neuroblastoma as part of immunotherapy to stimulate cytotoxic activity against GD2-positive neuroblastoma cells. Patients receiving the anti-GD2 monoclonal antibody dinutuximab are treated concomitantly with GM-CSF with favorable cure rates. There is no suitable alternative for GM-CSF. We present a patient enrolled in the ANBL1221 trial who presented with anaphylaxis to sargramostim. Hypersensitivity to GM-CSF and desensitization protocols are not well described in the literature. This case describes a successful subcutaneous desensitization protocol after multiple failed attempts at intravenous desensitization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
